Appeals allowed due to lack of evidence, parties to bear own costs

The Tribunal allowed the appeals, ruling that there was no deliberate misstatement in the prospectus and the utilization of IPO proceeds in ICDs did not violate ICDR Regulations. The Tribunal found the WTM's conclusions lacked evidence and were based on surmises. All appeals were allowed, and parties were directed to bear their own costs.

---

---

Issues Involved:
1. Misstatement in the Prospectus
2. Utilization of IPO Proceeds
3. Interim Use of Funds
4. Compliance with ICDR Regulations

Issue-wise Detailed Analysis:

1. Misstatement in the Prospectus:
The appellants were accused of making misleading statements in the prospectus regarding the utilization of IPO proceeds. The Whole Time Member (WTM) alleged that the company had no plan from the inception to utilize the funds as per the prospectus, thus committing fraud on IPO subscribers. The WTM concluded that the company’s resolution dated 11 July 2011, which included the word "corporate" for the temporary utilization of funds, indicated deliberate misstatements in the prospectus. However, the Tribunal found that the word "including" in the prospectus was illustrative and not exhaustive, thus covering ICDs under "liquid instruments." The Tribunal held that there was no misstatement in the prospectus, and the actions taken by the company did not indicate any deliberate misstatement or larger design to misuse the IPO proceeds.

2. Utilization of IPO Proceeds:
The company issued 6,51,75,000 equity shares, raising Rs. 65.17 crores, with the proceeds to be used for establishing 55 outlets, brand promotion, working capital, issue expenses, and contingencies. The WTM found that the company diverted Rs. 14 crores to support its share price on the listing day, disbursed Rs. 33.4 crores under false pretenses of work contracts, and invested Rs. 31 crores in ICDs to group companies, contrary to the prospectus. The Tribunal, however, noted that the subsequent non-utilization of IPO proceeds as per the prospectus does not imply a misstatement. It concluded that the company’s actions might be a violation of the terms and conditions of the prospectus but did not constitute a misstatement.

3. Interim Use of Funds:
The prospectus allowed for temporary investment of IPO proceeds in interest or dividend-bearing liquid instruments, including deposits with banks and mutual funds. The WTM argued that investing in ICDs was not specified and thus constituted a misstatement. The Tribunal countered this by interpreting "liquid instruments" broadly to include ICDs, referencing previous judgments like P.G. Electroplast v. SEBI, which held that non-mention of ICDs in the prospectus was a technicality and not a misstatement. The Tribunal emphasized that "liquid instruments" are those easily tradable and convertible to cash, which includes ICDs.

4. Compliance with ICDR Regulations:
The WTM found violations of Regulations 57(1), 60(4)(a), and 60(7)(a) of the ICDR Regulations, 2009, which require true, fair, and adequate disclosures in the offer document. The Tribunal disagreed, stating that the disclosures in the prospectus were material, true, fair, and adequate. It found no evidence that the disclosures were untrue or inadequate. The Tribunal held that the resolution of 11 July 2011 was in line with the prospectus and did not constitute a breach of the ICDR Regulations. Consequently, the Tribunal quashed the WTM’s findings and concluded that the appellants did not commit any breach of the ICDR Regulations or make any misstatement in the prospectus.

Conclusion:
The Tribunal allowed the appeals, quashing the impugned order against the appellants. It ruled that there was no deliberate misstatement in the prospectus, and the utilization of IPO proceeds in ICDs did not violate the ICDR Regulations. The Tribunal found the WTM’s conclusions to be based on surmises and conjectures, not supported by evidence. All appeals were allowed, and the parties were directed to bear their own costs.

---